{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=STA-9090",
    "query": {
      "intervention": "STA-9090"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=STA-9090&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T01:33:45.407Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01039519",
      "title": "A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastrointestinal Stromal Tumor"
      ],
      "interventions": [
        {
          "name": "Ganetespib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synta Pharmaceuticals Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2010-01",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2016-03-10",
      "last_synced_at": "2026-09-04T01:33:45.407Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01039519"
    },
    {
      "nct_id": "NCT01798485",
      "title": "A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small-Cell Lung Adenocarcinoma",
        "Non-small Cell Lung Cancer Stage IIIB",
        "Non-small Cell Lung Cancer Stage IV",
        "Non-small Cell Lung Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Ganetespib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synta Pharmaceuticals Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 696,
      "start_date": "2013-04",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2016-07-01",
      "last_synced_at": "2026-09-04T01:33:45.407Z",
      "location_count": 78,
      "location_summary": "Flagstaff, Arizona • Prescott Valley, Arizona • Sedona, Arizona + 66 more",
      "locations": [
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Prescott Valley",
          "state": "Arizona"
        },
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01798485"
    },
    {
      "nct_id": "NCT01554969",
      "title": "Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "capecitabine + ganetespib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2012-05",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2016-02-22",
      "last_synced_at": "2026-09-04T01:33:45.407Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01554969"
    },
    {
      "nct_id": "NCT00858572",
      "title": "STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AML",
        "CML",
        "MDS",
        "Myeloproliferative Disorders"
      ],
      "interventions": [
        {
          "name": "STA-9090 (ganetespib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synta Pharmaceuticals Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2009-03",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2014-09-18",
      "last_synced_at": "2026-09-04T01:33:45.407Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • San Antonio, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00858572"
    },
    {
      "nct_id": "NCT02334319",
      "title": "Ganetespib Window of Opportunity Study in Head and Neck Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage I Hypopharyngeal Squamous Cell Carcinoma",
        "Stage I Laryngeal Squamous Cell Carcinoma",
        "Stage I Oral Cavity Squamous Cell Carcinoma",
        "Stage I Oropharyngeal Squamous Cell Carcinoma",
        "Stage II Hypopharyngeal Squamous Cell Carcinoma",
        "Stage II Laryngeal Squamous Cell Carcinoma",
        "Stage II Oral Cavity Squamous Cell Carcinoma",
        "Stage II Oropharyngeal Squamous Cell Carcinoma",
        "Stage III Hypopharyngeal Squamous Cell Carcinoma",
        "Stage III Laryngeal Squamous Cell Carcinoma",
        "Stage III Oral Cavity Squamous Cell Carcinoma",
        "Stage III Oropharyngeal Squamous Cell Carcinoma",
        "Stage IVA Hypopharyngeal Squamous Cell Carcinoma",
        "Stage IVA Laryngeal Squamous Cell Carcinoma",
        "Stage IVA Oral Cavity Squamous Cell Carcinoma",
        "Stage IVA Oropharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ganetespib",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "19 Years to 79 Years"
      },
      "enrollment_count": 3,
      "start_date": "2014-12",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2016-07-26",
      "last_synced_at": "2026-09-04T01:33:45.407Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02334319"
    },
    {
      "nct_id": "NCT01562015",
      "title": "A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Ganetespib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synta Pharmaceuticals Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2012-04",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2015-05-20",
      "last_synced_at": "2026-09-04T01:33:45.407Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Cleveland, Ohio",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01562015"
    },
    {
      "nct_id": "NCT01227018",
      "title": "PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Pancreas",
        "Recurrent Pancreatic Cancer",
        "Stage IV Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "STA-9090",
          "type": "DRUG"
        },
        {
          "name": "Radiologic imaging",
          "type": "RADIATION"
        },
        {
          "name": "blood draw",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2010-12",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-07-23",
      "last_synced_at": "2026-09-04T01:33:45.407Z",
      "location_count": 2,
      "location_summary": "Memphis, Tennessee • Nashville, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01227018"
    },
    {
      "nct_id": "NCT02008877",
      "title": "SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malignant Peripheral Nerve Sheath Tumors (MPNST)",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "ganetespib",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarcoma Alliance for Research through Collaboration",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2013-12",
      "completion_date": "2018-07",
      "has_results": true,
      "last_update_posted_date": "2019-05-15",
      "last_synced_at": "2026-09-04T01:33:45.407Z",
      "location_count": 7,
      "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Iowa City, Iowa + 4 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02008877"
    },
    {
      "nct_id": "NCT01665937",
      "title": "STA-9090 in Patients With Advanced Hepatocellular Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "STA-9090",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2010-08",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2018-04-25",
      "last_synced_at": "2026-09-04T01:33:45.407Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01665937"
    },
    {
      "nct_id": "NCT01579994",
      "title": "Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Ganetespib (STA-9090) and crizotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2012-04-16",
      "completion_date": "2020-12-28",
      "has_results": false,
      "last_update_posted_date": "2020-12-30",
      "last_synced_at": "2026-09-04T01:33:45.407Z",
      "location_count": 5,
      "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rockville Centre",
          "state": "New York"
        },
        {
          "city": "Sleepy Hollow",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01579994"
    }
  ]
}